Condition
Recurrent Prostate Adenocarcinoma clinical trials and research
As of November 12, 2026, Find a Trial lists 2 Recurrent Prostate Adenocarcinoma clinical trials that are recruiting, in United States. By phase: Phase 2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 1Country
All recruiting trials (2)
-
PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer
This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.
-
Alpha- versus beta-emitting PSMA therapy plus targeted body radiation for recurrent oligometastatic prostate cancer
This tests whether adding either an alpha-emitting PSMA drug (225Ac-PSMA-617) or a beta-emitting PSMA drug (177Lu-PSMA-617) to precise stereotactic body radiotherapy helps control recurrent oligometastatic prostate cancer.
Related topics
Quick answers
How many Recurrent Prostate Adenocarcinoma clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in United States. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.